Notice: This company has been marked as potentially delisted and may not be actively trading. Tenzing Acquisition (TZAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TZAC vs. ALTS, STTK, IOBT, ITRM, FBIO, CELU, PRLD, VTVT, CASI, and KZRShould you be buying Tenzing Acquisition stock or one of its competitors? The main competitors of Tenzing Acquisition include Janone (ALTS), Shattuck Labs (STTK), IO Biotech (IOBT), Iterum Therapeutics (ITRM), Fortress Biotech (FBIO), Celularity (CELU), Prelude Therapeutics (PRLD), vTv Therapeutics (VTVT), CASI Pharmaceuticals (CASI), and Kezar Life Sciences (KZR). Tenzing Acquisition vs. Janone Shattuck Labs IO Biotech Iterum Therapeutics Fortress Biotech Celularity Prelude Therapeutics vTv Therapeutics CASI Pharmaceuticals Kezar Life Sciences Tenzing Acquisition (NASDAQ:TZAC) and Janone (NASDAQ:ALTS) are both small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of TZAC or ALTS? 60.9% of Tenzing Acquisition shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 37.5% of Tenzing Acquisition shares are owned by insiders. Comparatively, 4.9% of Janone shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is TZAC or ALTS more profitable? Tenzing Acquisition's return on equity of -13.32% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Tenzing AcquisitionN/A -13.32% -1.36% Janone N/A -2,940.01%-39.81% Which has better earnings & valuation, TZAC or ALTS? Tenzing Acquisition has higher earnings, but lower revenue than Janone. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenzing AcquisitionN/AN/A$620KN/AN/AJanone$7.11M7.60-$7.81MN/AN/A Which has more risk & volatility, TZAC or ALTS? Tenzing Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Janone has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Does the media refer more to TZAC or ALTS? In the previous week, Tenzing Acquisition's average media sentiment score of 0.00 equaled Janone'saverage media sentiment score. Company Overall Sentiment Tenzing Acquisition Neutral Janone Neutral Does the MarketBeat Community prefer TZAC or ALTS? Tenzing Acquisition and Janone both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformTenzing AcquisitionN/AN/AJanoneN/AN/A SummaryTenzing Acquisition beats Janone on 5 of the 7 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Tenzing Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TZAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TZAC vs. The Competition Export to ExcelMetricTenzing AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$6.87M$6.57B$1.95B$9.08BDividend YieldN/A3.00%14.47%4.23%P/E RatioN/A10.5911.0017.20Price / SalesN/A196.068,426.81117.04Price / Cash143.1057.1617.2237.85Price / Book1.375.092.014.78Net Income$620,000.00$151.83M-$986.87M$225.60M Tenzing Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TZACTenzing AcquisitionN/A$1.34-10.7%N/A-63.5%$6.87MN/A0.00N/AHigh Trading VolumeALTSJanoneN/A$3.77-3.8%N/AN/A$53.04M$7.11M0.00170Gap UpSTTKShattuck Labs2.6671 of 5 stars$1.09-4.4%$8.67+695.1%-82.2%$52.04M$1.66M-0.75100IOBTIO Biotech3.2871 of 5 stars$0.79-2.8%$9.33+1,085.9%-47.2%$51.85MN/A-0.5930News CoveragePositive NewsITRMIterum Therapeutics1.8276 of 5 stars$1.87+3.9%$5.00+167.4%+9.3%$51.46MN/A-0.9410FBIOFortress Biotech3.3437 of 5 stars$1.85-4.6%$13.67+638.7%-32.0%$51.07M$62.50M-0.63186CELUCelularity0.2712 of 5 stars$2.31+4.1%N/A+28.7%$50.79M$48.20M0.00220PRLDPrelude Therapeutics2.9419 of 5 stars$0.90+12.0%$4.00+346.6%-68.0%$49.29MN/A-0.52120News CoveragePositive NewsGap UpHigh Trading VolumeVTVTvTv Therapeutics2.0082 of 5 stars$15.44+2.7%$35.00+126.7%+69.8%$49.25M$2.02M-3.329Gap UpCASICASI Pharmaceuticals3.083 of 5 stars$3.15+1.3%$6.00+90.5%-60.4%$48.70M$22.06M-1.39180KZRKezar Life Sciences3.7131 of 5 stars$6.58-2.5%$40.50+515.5%-24.3%$48.01M$7M-0.5060Analyst ForecastNews Coverage Related Companies and Tools Related Companies Janone Competitors Shattuck Labs Competitors IO Biotech Competitors Iterum Therapeutics Competitors Fortress Biotech Competitors Celularity Competitors Prelude Therapeutics Competitors vTv Therapeutics Competitors CASI Pharmaceuticals Competitors Kezar Life Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TZAC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenzing Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenzing Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
